Compare, Analyse Dishman Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DISHMAN PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ADCOCK INGRAM
Jun-14
DISHMAN PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs374377-   
Low Rs129272-   
Sales per share (Unadj.) Rs197.8112.1-  
Earnings per share (Unadj.) Rs21.2-28.3-  
Cash flow per share (Unadj.) Rs34.7-23.4-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.988.0-  
Shares outstanding (eoy) m80.69168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.9 44.0%   
Avg P/E ratio x11.9-11.5 -103.3%  
P/CF ratio (eoy) x7.2-13.9 -52.3%  
Price / Book Value ratio x1.43.7 37.9%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,30654,766 37.1%   
No. of employees `0000.84.3 19.3%   
Total wages/salary Rs m5,3553,437 155.8%   
Avg. sales/employee Rs Th19,252.74,409.0 436.7%   
Avg. wages/employee Rs Th6,459.5800.7 806.8%   
Avg. net profit/employee Rs Th2,064.1-1,111.0 -185.8%   
INCOME DATA
Net Sales Rs m15,96118,928 84.3%  
Other income Rs m265133 200.2%   
Total revenues Rs m16,22619,061 85.1%   
Gross profit Rs m4,103-3,280 -125.1%  
Depreciation Rs m1,091817 133.5%   
Interest Rs m944513 184.2%   
Profit before tax Rs m2,334-4,477 -52.1%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624280 222.9%   
Profit after tax Rs m1,711-4,769 -35.9%  
Gross profit margin %25.7-17.3 -148.4%  
Effective tax rate %26.7-6.2 -427.7%   
Net profit margin %10.7-25.2 -42.5%  
BALANCE SHEET DATA
Current assets Rs m11,01813,863 79.5%   
Current liabilities Rs m9,5177,800 122.0%   
Net working cap to sales %9.432.0 29.4%  
Current ratio x1.21.8 65.1%  
Inventory Days Days110111 99.6%  
Debtors Days Days35124 28.1%  
Net fixed assets Rs m16,3048,081 201.8%   
Share capital Rs m16188 183.7%   
"Free" reserves Rs m12,9070-   
Net worth Rs m14,51614,856 97.7%   
Long term debt Rs m4,1895,221 80.2%   
Total assets Rs m29,80528,065 106.2%  
Interest coverage x3.5-7.7 -44.9%   
Debt to equity ratio x0.30.4 82.1%  
Sales to assets ratio x0.50.7 79.4%   
Return on assets %8.9-15.2 -58.7%  
Return on equity %11.8-32.1 -36.7%  
Return on capital %17.5-19.8 -88.5%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Net fx Rs m4,2550-   
CASH FLOW
From Operations Rs m2,7861,616 172.5%  
From Investments Rs m-1,529-496 308.2%  
From Financial Activity Rs m-9414,738 -19.9%  
Net Cashflow Rs m3165,858 5.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.2 Rs / ZAR

Compare DISHMAN PHARMA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare DISHMAN PHARMA With: FULFORD INDIA  BIOCON   WOCKHARDT  DIVIS LABORATORIES  J.B.CHEMICALS  



Today's Market

SGX Nifty Up 60 Points, 6 Reasons Behind the Stock Market Crash, HDFC Bank Q4FY21 Results, and Buzzing Stocks Today(Pre-Open)

Indian share markets nosedived and registered sharp losses in yesterday's volatile session following a strong second wave of Covid-19 in the country.

Related Views On News

Most Popular

India: Recovery Stalled by Vaccine Games? (The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story (Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday? (Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits (Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Report: Multibagger Stock Ideas 2021
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - STERLING BIOTECH COMPARISON

COMPARE DISHMAN PHARMA WITH

FEATURED VIDEOS

Stability, Quality or Green Stocks for 2021?

Market Crash: Picture Abhi Baaki Hai?

It's a Great Time to Buy Gold

The Dilemma of Investing in Bharti Airtel

More Featured Videos

MARKET STATS